Saturday 17 October 2026
Export SCNI’s income statement to Excel — free account
Scinai Immunotherapeutics Ltd. Sponsored ADR
SCNI Healthcare Biotechnology
Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024. In the quarter to June 2026, EPS grew 100.4% and free cash flow grew 51.1%, each against the same quarter a year earlier.
0.75
0.15
−16.67%
Follow SCNI
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.07 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 0.00 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (1.48) | — | — | |
P/B ratio |
— | 0.35 | — | — | |
Price to Tangible BV |
— | 0.35 | — | — | |
EV/Sales |
— | 0.00 | — | — | |
EV/EBITDA |
— | 0.06 | — | — | |
EV/Operating CF |
— | 0.05 | — | — | |
EV/FCF |
— | 0.05 | — | — | |
Quick Ratio |
1.56 | 1.35 | 1.30 | 0.71 | |
Current Ratio |
1.56 | 1.35 | 1.30 | 0.71 | |
Net Debt/EBITDA |
0.00 | 1.40 | 0.00 | 0.00 | |
Debt/Assets |
1.66% | 1.63% | 2.53% | 2.47% | |
Debt/Equity |
0.02 | 0.02 | 0.04 | 0.04 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | (0.41) | — | 0.00 | |
Capex/Depreciation |
(0.19) | (0.01) | — | (0.01) | |
Interest Coverage |
— | (22.03) | — | — | |
Research and Development Expense of Revenue |
— | 128.43% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 147.44% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 14.31% | — | 0.00% | |
Graham Net Nets |
— | (1.03) | — | — | |
Graham Number |
— | 176.28 | — | — | |
Earnings Yield |
— | 1,495.86% | — | — | |
Free Cash Flow Yield |
— | (431.62%) | — | — | |
Revenue per Share |
— | 1.29 | — | — | |
Operating CF per Share |
0.00 | (3.84) | — | 0.00 | |
Capex per Share |
0.00 | (0.01) | — | 0.00 | |
Free Cash Flow per Share |
0.00 | (3.85) | — | 0.00 | |
Cash per Share |
0.00 | 8.22 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 31.06 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 31.06 | 0.00 | 0.00 | |
Free Cash Flow |
(2.58) | (1.46) | — | (1.54) | |
Working Capital |
1.26 | 0.93 | 0.47 | (0.61) | |
Capital Expenditures |
(0.11) | 0.00 | — | 0.00 | |
Net Current Asset Value |
(1.95) | (2.21) | (1.47) | (2.48) | |
EV/EBIT |
— | 0.05 | — | — | |
Capex to Sales |
0.00 | 0.01 | — | 0.00 | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.54 | 0.47 | 0.27 | 0.41 | |
Average Payables |
0.64 | 0.72 | 0.67 | 0.60 | |
Average Assets |
14.72 | 16.22 | 14.34 | 14.66 | |
Average Common Equity |
5.24 | (0.57) | (1.32) | (1.17) |
Columns are period end dates